Y-mAbs Reports MAA Submission to EMA for Omburtamab to Treat Pediatric Patients with CNS/Leptomeningeal Metastasis from Neuroblastoma

  • by

Shots:

  • The company has submitted MAA for Omburtamab to EMA for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma
  • The company continues to advance the Omburtamab program addressing the unmet medical need globally and work closely with FDA to resubmit the BLA in Q2 or Q3’21
  • Y-mAbs get an exclusive license from MSK while MSK has an institutional financial interest related to the compound and Y-mAbs. Omburtamab is mAb targeting B7-H3 and is radiolabeled before intraventricular CNS administration

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: Y-mabs

The post Y-mAbs Reports MAA Submission to EMA for Omburtamab to Treat Pediatric Patients with CNS/Leptomeningeal Metastasis from Neuroblastoma first appeared on PharmaShots.